Easy Medical Device Podcast

Exploring AI-Assisted Clinical Evaluation with Ethan Drower from CiteMed

Artificial Intelligence is changing how medical device companies approach documentation, information management, and regulatory activities.

One area attracting increasing attention is Clinical Evaluation.

AI-powered tools promise to support literature reviews, organize clinical evidence, generate structured documentation, and potentially reduce the time required to prepare Clinical Evaluation Reports (CERs).

But an important question remains:

Can AI actually write a Clinical Evaluation Report, or does the process still depend on experienced clinical evaluation professionals?

In this episode of Medical Device Made Easy, we welcome Ethan Drower from CiteMed to explore the practical possibilities and limitations of AI-assisted clinical evaluation.

The conversation follows the journey from preparing the necessary inputs to reviewing the finished documentation, examining where AI may provide value and where qualified human expertise remains essential.

Can Someone Without Clinical Evaluation Experience Use AI to Write a CER?

One of the most important questions surrounding AI-assisted clinical evaluation is whether these tools make the process accessible to professionals without specific clinical evaluation experience.

Could a QA/RA professional who has never written a Clinical Evaluation Report use AI software to prepare one?

And if so, where would they still need guidance?

The episode explores the difference between using software to generate documentation and possessing the expertise required to assess its scientific and regulatory adequacy.

While AI may assist with certain activities, interpreting clinical evidence, evaluating its relevance, and supporting conclusions require appropriate knowledge and judgment.

Preparing the Right Inputs Before Using AI

A useful clinical evaluation workflow begins long before opening an AI tool.

Manufacturers need to understand the device being evaluated and establish a clear foundation for the evaluation.

This includes:

Device information and characteristics.

Intended purpose and clinical claims.

Available clinical evidence.

Clinical evaluation strategy.

Documentation structure and templates.

The discussion also considers how document templates can influence AI-assisted workflows.

A clear and consistent structure may support efficient documentation, while poorly designed templates can introduce unnecessary complexity.

AI output depends heavily on the quality and organization of the information provided.

How Can AI Support Literature Review and Evidence Collection?

Literature review is a critical component of clinical evaluation and can involve significant effort.

Identifying relevant publications, screening search results, extracting information, and organizing evidence all require time and attention.

The episode explores how AI tools may assist with different stages of this process, including literature screening, summarization, and the preparation of evidence tables.

However, AI-generated recommendations should not automatically determine which studies are included or excluded.

Qualified evaluators must assess the relevance, quality, and applicability of the evidence.

The objective is to explore how automation can reduce repetitive work without weakening the scientific foundation of the clinical evaluation.

From Clinical Evidence to a Draft Clinical Evaluation Report

Once relevant evidence has been collected, the next challenge is transforming it into coherent clinical evaluation documentation.

AI may help organize information and prepare draft sections, but a Clinical Evaluation Report must do more than summarize publications.

It needs to connect the available evidence to the device's intended purpose, clinical claims, safety, and performance.

The conversation explores how AI-assisted workflows can support this process while maintaining traceability.

Important questions include:

Can every significant statement be traced back to its source?

Does the available evidence actually support the proposed conclusion?

What happens when the evidence is incomplete, conflicting, or insufficient?

These questions demonstrate why clinical evaluation remains an evidence-based professional activity rather than simply a documentation exercise.

A Convincing AI-Generated CER Is Not Necessarily a Good CER

Generative AI can produce professional-looking documentation.

But clear writing and confident conclusions do not automatically demonstrate scientific validity.

The episode examines how experienced professionals can evaluate AI-generated reports and identify potential problems.

These may include unsupported claims, missing information, inaccurate summaries, inappropriate interpretation of evidence, or conclusions that are not justified by the available data.

The quality of a Clinical Evaluation Report depends on the quality of its evidence and reasoning—not simply how well it is written.

Appropriate review and approval remain essential parts of the process.

Can AI Really Save Time and Resources?

Efficiency is one of the main reasons manufacturers are interested in AI-assisted clinical evaluation.

But where can meaningful savings actually occur?

The discussion explores activities that may benefit from automation, including literature screening, information extraction, evidence organization, and initial drafting.

It also considers the work that continues to require significant human effort, such as critical appraisal, interpretation, review, and approval.

Another important consideration is whether the benefits differ between preparing a first Clinical Evaluation Report and updating an existing one.

For manufacturers evaluating AI tools, the key is to measure practical value rather than assuming that automation will automatically reduce overall costs.

Training Teams and Introducing AI into Clinical Evaluation

Adopting AI-assisted clinical evaluation involves more than learning how to operate software.

Teams need to understand the clinical evaluation process itself, the limitations of the technology, and the controls necessary to maintain reliable documentation.

The episode explores how manufacturers can introduce these workflows through manageable pilot projects.

It also examines when existing AI tools may be sufficient and when a dedicated platform could provide additional support.

For experienced clinical evaluation writers, successful adoption may depend on demonstrating how the technology can complement their expertise rather than attempting to replace their established methods.

Discovering CiteMed's Approach

During the conversation, Ethan Drower also introduces CiteMed and discusses its approach to supporting clinical evaluation activities.

The discussion includes the types of workflows its platform supports, the professionals it is designed for, and the onboarding or training available to customers.

This provides an opportunity to understand how dedicated software solutions may fit into existing clinical evaluation processes.

Final Takeaway: AI Can Assist, but Clinical Judgment Still Matters

Artificial Intelligence has the potential to support clinical evaluation workflows by helping professionals manage information, organize evidence, and prepare documentation more efficiently.

However, clinical evaluation cannot be reduced to automatically generating a report.

It requires a clear evaluation strategy, appropriate evidence, scientific reasoning, traceability, and qualified review.

AI can help write the document. But qualified professionals must ensure that the evidence supports the conclusions.

For medical device manufacturers, the opportunity lies in combining the efficiency of AI-assisted tools with the knowledge and judgment of experienced clinical evaluation professionals.

🎙️ In this episode of Medical Device Made Easy, Ethan Drower from CiteMed helps explore what that balance could look like in practice.

Can AI really write your Clinical Evaluation Report? Discover where technology can help—and where human expertise remains indispensable.

Who is Monir El Azzouzi? 

Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. 

Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: [email protected]

Links

Ethan Drower's linkedin: https://www.linkedin.com/in/ethandrower/

CiteMed: https://citemed.com/podcast-materials/

CiteMed's linkedin: https://www.linkedin.com/company/getcitemed/

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Small Business, Smart Start: AI Without Complex Infrastructure

Artificial Intelligence is creating new opportunities for businesses to improve productivity, simplify workflows, and reduce repetitive administrative work.

However, for many small medical device companies, adopting AI can feel overwhelming.

Where should you begin? Which processes are worth automating? Do you need expensive infrastructure or a dedicated development team? And how can you ensure that an AI assistant delivers reliable results?

In this episode of Medical Device Made Easy, we welcome Helder Conceicao to explore how small businesses can take their first practical steps with AI agents.

With experience in service engineering, business processes, and supporting AI adoption in small companies, Helder brings a practical perspective to a topic that is often presented as more complicated than it needs to be.

Understanding AI Agents: Beyond Traditional Chatbots

Many professionals have already experimented with AI tools to answer questions, draft emails, or summarize information.

But an AI agent introduces a different way of thinking about how AI can support business processes.

Rather than focusing only on individual conversations, the discussion explores how AI assistants can support defined tasks and workflows.

Helder explains the differences between traditional chatbots and AI agents, including what these solutions can accomplish and where human involvement remains necessary.

The objective is to help business owners understand the practical possibilities before investing in a solution.

Choosing the Right First AI Project

One of the biggest challenges in AI adoption is deciding where to begin.

Businesses may have dozens of processes that could potentially benefit from automation, but not every task is a good starting point.

The conversation explores how to identify a first project based on a genuine operational need.

For medical device companies, potential areas to investigate include:

Documentation: Supporting document preparation, organization, and information retrieval.

Quality and Regulatory Affairs: Assisting with administrative activities and information management while maintaining appropriate human review.

Field Service: Exploring ways to support service-related workflows and routine processes.

The key is to identify a manageable use case with a clear purpose and measurable value.

From an Idea to a Working AI Assistant

Once a company has identified a suitable process, what happens next?

The episode explores the journey from an initial business problem to a functioning AI solution.

This includes understanding what information the company needs to prepare, how the workflow should operate, and what technical resources may be required.

An important part of the discussion is determining whether an existing AI platform can meet the company's needs or whether additional development and infrastructure are necessary.

For smaller organizations, these decisions can have a significant impact on project complexity, cost, and implementation time.

How Much Does AI Implementation Really Require?

Cost and resources are common concerns for businesses considering AI.

Does every AI project require a large budget? How much time should the company expect to invest? And how involved does the internal team need to be?

Helder discusses the practical considerations behind planning an AI implementation, including the importance of defining the project's scope and understanding the resources required.

The goal is to help businesses approach AI adoption with realistic expectations rather than assuming that every solution requires a major technology investment.

Keeping Humans in Control

For medical device companies, automation must be considered alongside reliability, accountability, and appropriate oversight.

Not every task should be delegated to AI without review.

The conversation addresses how to determine which activities an AI assistant can support independently and which require a qualified person to review, approve, or make the final decision.

It also explores how businesses can test whether an AI assistant is sufficiently reliable for its intended task, particularly when working with important company documents.

AI should support better business processes without removing necessary human judgment and responsibility.

Measuring the Value of Your First AI Project

Implementing an AI assistant is only the beginning.

The next question is whether the solution actually improves the business process it was designed to support.

The discussion examines common challenges encountered during initial AI projects and how businesses can evaluate their results.

Potential considerations include time saved, reduced repetitive work, improved workflow efficiency, and the level of human intervention still required.

Understanding these outcomes can help a company decide whether to improve its first solution or move toward another use case.

Building Independence and Long-Term Capability

An AI solution should not necessarily leave a company dependent on the person who originally developed it.

The episode also explores the importance of documentation, knowledge transfer, and ongoing support.

Helder discusses how businesses can understand the solutions implemented for them, how they may operate those solutions independently, and what additional assistance could be available after deployment.

This is particularly relevant for small companies that want to develop their internal capabilities while keeping their technology manageable.

Final Takeaway: Start Small, Learn, and Expand

AI adoption doesn't have to begin with a company-wide transformation.

For small medical device businesses, a useful first step is to identify one process that consumes time, creates repetitive work, or could benefit from better information management.

Then explore whether an AI assistant can help.

Start with a clear problem. Build a focused solution. Test the results. Keep people involved where necessary. Measure the value.

Once the first project demonstrates its usefulness, the company can consider what comes next.

In this episode of Medical Device Made Easy, Helder Conceicao helps make the first steps toward AI adoption more understandable and practical for small businesses.

What is one business task you would like AI to help you improve?

Who is Helder Conceição?

Helder Conceição is the founder of heconexus®, helping small businesses in Portugal adopt AI in their everyday work. He brings more than 25 years of experience at Johnson & Johnson across local, European and global roles, spanning service engineering, business processes and digital initiatives. His approach focuses on practical processes, measurable value, human oversight and helping teams become confident and autonomous in their use of AI.

Links

LinkedIn: https://www.linkedin.com/in/helderconceicao/ 

AI in SMEs: where to start improving everyday work

https://www.linkedin.com/pulse/ia-nas-pmes-por-onde-começar-para-melhorar-o-trabalho-conceição-bptae/

 choosing a useful first process, testing with the team and measuring value.

Which AI is best for your company?

https://www.linkedin.com/feed/update/urn:li:activity:7514233631742164992/

 choosing a platform around a real business task and the company’s needs.

One successful AI example: is that enough for the team to start using it?

https://www.linkedin.com/feed/update/urn:li:activity:7510972255170994176/

testing varied cases, checking sources and defining human review.

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

October brings another important round of regulatory developments for the medical device and IVD industry. From updated IVD classification guidance in Europe and potential changes to the UK medical device licensing framework, to new FDA expectations for robotically assisted surgical devices, radiology AI, PMA submissions, and international regulatory reliance, manufacturers have several developments worth following closely.

Here is our Medical Device Regulatory Update for October 2026, supported by regulatory intelligence from MedBoard.

🇪🇺 European Union – Revised IVD Classification Guidance

The European Commission has published MDCG 2020-16 Rev.5, updating the guidance on classification rules for in vitro diagnostic medical devices under the IVDR.

For IVD manufacturers, classification is a fundamental regulatory decision that can affect the conformity assessment route and regulatory strategy.

👉 MDCG 2020-16 Rev.5 – Guidance on Classification Rules for IVDs

🇬🇧 UK – The Door Opens to Direct MHRA Licensing

Proposed amendments to the UK Government's Health Bill could create powers supporting the future development of a medical device licensing regime.

The amendments also address information-sharing powers for medicines and medical devices and measures intended to make medicines and medical-device legislation easier to update.

This is an important development to watch for manufacturers planning access to the UK market.

👉 MHRA Regulatory Reform Amendments – Health Bill

🇬🇧 MHRA Warning – Incompatible Components Continue to Cause Serious Incidents

The MHRA has highlighted ongoing safety concerns involving patient hoists and incompatible components.

The warning is an important reminder that medical-device safety does not stop with individual component compliance. Compatibility between components, accessories and systems can directly affect patient safety.

Manufacturers and healthcare organizations should pay close attention to compatibility information, instructions for use and the way devices are combined in real-world environments.

👉 MHRA – Steps to Prevent Avoidable Harm from Patient Hoists

🇨🇭 swissdamed – Importer Linking Is Now Operational

Another important development comes from Switzerland.

Swiss importers can now link their CHRN to imported devices in swissdamed.

This adds another operational consideration for manufacturers and importers working in the Swiss medical-device market, particularly as swissdamed becomes increasingly important within the country's regulatory infrastructure.

👉 Swissmedic – Information for Importers in swissdamed

🌍 Rest of the World

🇺🇸 FDA – Robotically Assisted Surgical Devices

The FDA has issued draft guidance addressing robotically assisted surgical devices.

The guidance covers areas including non-clinical testing, clinical evidence and labeling for teleoperated surgical systems.

For manufacturers developing robotic surgical technologies, understanding these expectations early can help inform development, testing and premarket strategy.

👉 FDA – Robotically Assisted Surgical Devices: Premarket Submissions

🤖 FDA Rejects Proposed 510(k) Exemption for Radiology AI Devices

AI remains firmly on the regulatory agenda.

The FDA has rejected a proposed exemption from premarket notification for certain radiology computer-aided detection, diagnosis and triage devices.

The practical message for manufacturers is clear: these products must continue to obtain the applicable FDA clearance before being marketed.

👉 FDA – Radiology Computer-Aided Detection, Diagnosis and Triage Devices

🇺🇸 FDA Moves PMA Applications Toward Structured Electronic Submissions

The FDA is also moving toward a more structured approach to electronic Premarket Approval (PMA) applications.

Draft guidance introduces electronic resources and templates intended to improve submission consistency and review efficiency.

Manufacturers working on PMA submissions should follow this development as electronic submission structures continue to evolve.

👉 FDA – Electronic Submission Template for PMA Applications

🌐 FDA Creates a Regulatory Reliance Resource Centre

International regulatory reliance continues to gain attention.

The FDA has created a dedicated CDRH Regulatory Reliance Portal explaining how other regulatory authorities can leverage FDA regulatory work and decisions while retaining their own national sovereignty and decision-making responsibilities.

For an increasingly global medical-device industry, regulatory reliance could play an important role in reducing unnecessary duplication and supporting more efficient regulatory processes.

👉 FDA CDRH Regulatory Reliance Portal

🛠️ What's New at Easy Medical Device?

Alongside this month's regulatory developments, Easy Medical Device continues to expand the resources and services available to medical-device companies.

EasyIFU

EasyIFU supports medical-device manufacturers working with electronic Instructions for Use.

👉 Discover EasyIFU

New Partner Services

New partner services are also available in areas including:

Software Development & Cybersecurity

Company Creation

These services expand the support available to medical-device companies across different stages of their development and market-access journey.

🎙️ Latest Easy Medical Device Podcast Episodes

October is also a good opportunity to catch up on the latest Medical Device Made Easy episodes.

Episode 406 – Your Technical Documentation Has All the Documents… So Why Isn't It Ready?

Having every document does not necessarily mean your Technical Documentation is assessment-ready. This episode explores adequacy, consistency, evidence and traceability across the dossier.

👉 Listen to Episode 406

Episode 407 – Why Management Doesn't Listen to Quality and How to Change That

Why do Quality and Regulatory teams sometimes become isolated from the rest of the organization? This episode explores the shift from being the “Quality Police” to becoming a Quality Influencer.

👉 Listen to Episode 407

Episode 408 – Vertical Slicing for Complex SaMD Development

Complex SaMD development can become fragmented when teams focus on individual components. This conversation explores vertical slicing as a way to look at functionality and clinical workflows end-to-end.

👉 Listen to Episode 408

Episode 409 – AI Is Already Inside Your QMS – But Is It Under Control?

AI may already be used by Quality, Regulatory, Engineering and PMS teams—even without a formal company-wide AI initiative.

This episode discusses Shadow AI, risk-based AI control, verification, human accountability and how Quality teams can approach AI without simply banning it.

👉 Listen to Episode 409

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Artificial Intelligence may already be part of your Quality Management System, even if your organization has never formally implemented an AI tool.

Regulatory Affairs professionals may use ChatGPT to research requirements. Quality teams may use AI to help draft procedures or summarize meetings. Engineers may ask AI to brainstorm potential failure modes. Post-Market Surveillance teams may experiment with AI to analyze complaints.

This creates an important challenge:

AI may already be inside your QMS—even though your QMS doesn't know it. Markdown collé

The answer isn't necessarily to ban AI.

The answer is to understand where it is being used and introduce controls proportionate to the risk.

The Shadow AI Problem

Employees don't always wait for management to formally implement AI.

When a tool can turn a three-hour activity into a thirty-minute task, people naturally become interested.

The Quality challenge isn't simply that AI is being used. The problem is that the organization may not know:

what activities AI supports, what information employees provide to it, how outputs are verified, and how heavily people rely on those outputs.

This is what the episode describes as Shadow AI. Markdown collé

Not Every AI Use Has the Same Risk

Asking AI to improve the wording of an email isn't equivalent to asking it to determine whether complaint data indicates a safety signal.

The key question is:

What happens if the AI is wrong?

An error in a rewritten email may have limited consequences. An incorrect conclusion about complaint reportability or patient safety could have significantly different consequences.

AI governance should therefore be based on intended use and risk, rather than treating every AI application identically. Markdown collé

Green, Amber, Red: A Practical AI Framework

The episode introduces a simple traffic-light approach.

🟢 Green — Assist

AI improves productivity without materially driving a regulated decision.

Examples include improving English, formatting documents, brainstorming, summarizing meeting notes or helping structure a presentation.

Normal human review, together with appropriate confidentiality and information-security controls, may be sufficient for these lower-risk applications.

🟠 Amber — Verify

AI begins influencing regulated work.

Examples include helping draft an SOP, suggesting potential FMEA failure modes, summarizing complaints, researching regulatory requirements or suggesting possible CAPA root causes.

The principle here is simple:

AI can propose. A qualified person must verify.

AI can help locate information, but it shouldn't automatically become the regulatory evidence supporting a decision.

🔴 Red — Assess Before Deployment

Here, AI makes or materially drives a critical decision.

Examples could include automatically determining complaint reportability, accepting suppliers, closing CAPAs, deciding risk acceptability or generating clinical conclusions without independent qualified evaluation.

These uses call for formal assessment before the organization relies on the system. Markdown collé

Human Review Is Not Automatically Verification

“We have a human reviewing everything” sounds reassuring.

But what does review actually mean?

Generative AI can produce incorrect information that looks professional and convincing. Reading an AI-generated regulatory assessment and thinking “looks good” isn't necessarily meaningful verification.

The episode proposes another important principle:

Trust the source, not the sentence.

Regulatory requirements should be checked against the regulation. Complaint-analysis results should be checked against the underlying data and methodology. Technical suggestions should be evaluated by qualified personnel. Markdown collé

Five Steps for Bringing AI Under Control

Rather than immediately writing an AI SOP, the episode recommends starting with discovery.

First, inventory where AI is already being used.

Then classify each use according to what could happen if the output is wrong.

Next, control the input, particularly where patient information, complaints, confidential drawings, clinical data, intellectual property or supplier information may be involved.

After that, define how the output will be verified.

Finally, maintain human accountability.

As the episode puts it:

“AI can perform work. It cannot inherit your regulatory accountability.” Markdown collé

What About AI Validation?

Instead of starting with:

“Do we need to validate ChatGPT?”

Start by asking:

What exactly are we using it for?

Then:

What happens if it gives us the wrong answer?

And finally:

What level of assurance do we need for that intended use?

The framework presented in the episode is:

Intended Use → Risk → Control → Evidence. Markdown collé

AI Literacy Matters Too

AI governance isn't only about procedures and technical controls.

People need to understand what AI does well, where it can fail, how errors and hallucinations can occur, how information should be verified, what data they are allowed to enter, and when AI should not be relied upon.

That's a much more practical form of AI literacy than simply asking employees to click through another annual training presentation. Markdown collé

AI Isn't the Enemy of Quality

The message of the episode isn't to avoid AI.

Quite the opposite.

AI could create significant opportunities for Quality and Regulatory teams—from supporting complaint analysis and regulatory intelligence to identifying recurring CAPA themes, simplifying procedures, creating training exercises, checking Technical Documentation for inconsistencies, and brainstorming potential hazards for qualified professionals to assess. Markdown collé

The role of Quality shouldn't be to stand in front of innovation and say:

“No, because compliance.”

It should be to enable innovation with appropriate controls.

Final Takeaway

Instead of asking your team:

“Are you using ChatGPT?”

Ask:

“Show me where AI is helping you do your job today.”

Then build the inventory and ask what happens if the AI gets each task wrong.

Green: Assist.
Amber: Verify.
Red: Assess before deployment.

Control the inputs. Verify the outputs. Keep humans accountable.

Because banning AI may not stop its use, while ignoring it means losing visibility.

A better approach is:

Understand it. Control it. Use it. Markdown collé

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Developing complex Software as a Medical Device (SaMD) can quickly become challenging.

Requirements, software architecture, dependencies, risk management, verification, regulatory evidence, and cross-functional collaboration all need to work together.

But what happens when individual software components appear to work correctly while the complete end-to-end workflow reveals something different?

In this episode of the Easy Medical Device Podcast, Monir El Azzouzi welcomes Shreya Sridhar from Medtronic to explore vertical slicing for complex regulated software products.

Rather than looking at a system only through individual components or technical layers, vertical slicing provides a way to examine functionality end-to-end.

In this episode, we discuss:

🔹 What vertical slicing means in practice
🔹 The challenges of developing complex SaMD
🔹 How end-to-end workflows can reveal hidden problems
🔹 How to structure vertical slices
🔹 Integrating vertical slicing into Agile development
🔹 Risk management, verification, and regulatory evidence
🔹 Vertical slicing alongside Design Controls
🔹 Cross-functional collaboration in regulated development
🔹 What “Done” means for a vertical slice in a medical device environment
🔹 The potential role of vertical slicing as AI supports requirements, code, testing, and documentation
🔹 Practical advice for teams that want to start using the approach

The conversation connects software development with the realities of regulated medical device development, looking beyond whether individual components work to understand whether the complete functionality works as intended.

Who is Shreya Sridhar?

Shreya Sridhar is a Principal Systems Engineer and technical leader specializing in complex Software as a Medical Device (SaMD) and AI-enabled medical technologies. Her work focuses on systems architecture, requirements, risk management, verification, and cross-functional product development. She has published and presented on systems engineering, vertical slicing, and the development of complex regulated software, with a particular focus on connecting product strategy to end-to-end engineering execution.   

Who is Monir El Azzouzi? 

Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. 

Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: [email protected]

 If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.

Links

Shreya LinkedIn: https://www.linkedin.com/in/shreyasridhar/ 

Links to Articles on Vertical Slicing: 

1. Designing SaMD for safety and rethinking risk management through system architecture 

2. Decomposing Complexity: A Systems Engineering View of Modern Software — Aligning the V-Model with a Slicing-Based Decomposition Strategy 

3. Your roadmap is not a feature list: A two-level slicing framework for better release planning 

4. Vertical Slicing as a Foundation for SaMD Development in the Age of Agentic AI 

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Quality and Regulatory professionals often find themselves in a frustrating position.

They identify a problem, explain the compliance risk and recommend an action. But instead of being seen as protecting the organization, they can become perceived as the people creating obstacles.

Operations sees a delayed project. Finance sees additional resources. Management sees another problem that needs to be solved.

Over time, this dynamic can leave QA/RA professionals frustrated, isolated and exhausted.

But the problem isn't always management.

Sometimes, the way Quality operates can unintentionally contribute to that isolation.

When Quality Owns Everything

Consider a nonconformity that occurs in Production.

In some organizations, Quality opens the record, writes the description, gathers the evidence, conducts much of the investigation, pushes for the root cause, proposes the corrective action and follows the issue until closure.

The problem happened in Production—but Quality performed almost all the work.

The organization eventually learns a dangerous lesson:

“When something goes wrong, send it to Quality.”

This creates dependency instead of ownership.

A better principle is:

Ownership stays with the process owner. Quality provides the framework and the challenge.

The Quality Tyrant, Invisible Manager and Influencer

Under pressure, QA/RA professionals can fall into three different behaviours.

The Quality Tyrant tries to create compliance through control. They take over investigations, impose solutions and attempt to own every decision.

The Invisible Quality Manager moves in the opposite direction. They avoid difficult conversations, accept weak justifications and may close issues before they have been properly understood.

The Quality Influencer takes a different approach.

They involve the people closest to the process, separate facts from assumptions, challenge weak root causes, verify that actions address the actual problem and keep responsibility with the process owner.

Quality Shouldn't Be the Human Shield During an Audit

Another sign of an ownership problem appears when an auditor asks Production a question—and everyone immediately looks at the Quality Manager.

A mature QMS isn't demonstrated by how well Quality can answer every question.

It's demonstrated by how naturally employees can explain and perform their own activities.

When the auditor asks about Purchasing, Purchasing should answer. When the question concerns Production, Production should explain the process.

Quality can coordinate, clarify requirements and help locate evidence—but it shouldn't become a human shield between the auditor and the organization.

Training Completion Isn't the Same as Competence

A dashboard showing 100% training completion looks reassuring.

But what does an electronic acknowledgement actually prove?

It proves that someone acknowledged the document—not necessarily that they understood the change or can perform the activity correctly.

Training methods should therefore be proportionate to the activity, its complexity and its risk. Depending on the situation, competence might require a discussion, scenario-based questions or practical demonstration rather than another signature.

Stop Creating Procedures for an Imaginary Company

Quality can also lose credibility by designing processes that the organization cannot realistically operate.

More signatures, approvals, meetings and forms don't automatically create a stronger QMS.

Patient safety, product performance and legal requirements are non-negotiable—but QA/RA professionals also need to distinguish between a genuine requirement and a preferred way of meeting that requirement.

An effective approach understands the regulatory objective and works with the organization to find a practical, proportionate and defensible way to achieve it.

From Quality Police to Quality Influencer

Management doesn't make decisions using regulatory language alone.

Simply saying “Clause X requires us to do this” may be technically correct, but it doesn't always help decision-makers understand the impact.

An influential QA/RA professional translates regulatory concerns into consequences management can evaluate.

That means speaking several languages:

Regulation → Patient/User Risk → Operations → Finance → Management Decisions

Influence starts when people understand how a Quality concern affects the objective they're trying to achieve.

Bring Options, Not Only Obstacles

Management meetings are decision-making environments.

When possible, Quality should explain the problem, identify the non-negotiable regulatory or safety boundaries, and present possible paths forward.

Some situations allow different compliant approaches. Others don't: a legal obligation doesn't become optional because the project is late, and an unacceptable safety risk cannot simply be accepted because fixing it is expensive.

The role of QA/RA is to inform, warn and guide, while escalating appropriately when necessary.

Quality Is a Collective Responsibility

When one Quality professional becomes the author of every nonconformity, owner of every CAPA, coordinator of every audit, author of every procedure and reminder system for every overdue action, burnout becomes almost inevitable.

The solution isn't another time-management technique.

It's moving from individual dependency to collective ownership.

Quality should build the system, support the people operating it, challenge the evidence and monitor effectiveness. But the organization must own the activities that actually create product quality.

Final Takeaway

The goal of QA/RA isn't to win every argument, become the most feared department or keep every dashboard green.

The goal is to improve the quality of the organization's decisions.

Don't become the Quality Tyrant.

Don't disappear as the Invisible Quality Manager.

Become the Quality Influencer who connects regulatory expectations, patient safety and business reality.

Who is Monir El Azzouzi? 

Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. 

Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: [email protected]

 If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

A company says its Medical Device Technical Documentation is 90% or 95% ready.

The Risk Management File exists. The Clinical Evaluation is complete. Testing has been performed. The GSPR checklist and IFU are available.

But there's an important question:

95% of what?

Having all the expected documents doesn't necessarily mean your Technical Documentation is ready for assessment. Like a puzzle, you can have every piece on the table—but if some pieces are outdated, others belong to a different version of the product, and several don't fit together, the puzzle isn't complete.

1. Start With the Product, Not Annex II

Instead of immediately opening an Annex II template and looking for documents to fill each section, start with a more fundamental question:

What exactly are we trying to certify?

Your intended purpose, patient population, intended users, use environment, indications, contraindications, lifetime, claims, variants and accessories should provide a common source of truth across the Technical Documentation.

If Marketing makes a claim that isn't reflected in the intended purpose, Clinical Evaluation or Risk Management File, you may already have a significant consistency problem.

2. Challenge Your Regulatory Assumptions

“It's Class IIa because our competitor is Class IIa” isn't a classification rationale.

Early assumptions about qualification, classification and conformity assessment can influence testing, clinical strategy, budget and Notified Body involvement.

Those assumptions should therefore be challenged and properly documented before they become expensive to change.

3. Use the GSPR to Build the Dossier

The GSPR shouldn't simply appear at the end of the project as another checklist.

For every applicable requirement, ask:

How will we demonstrate conformity?

That means identifying the relevant standard, specification, analysis, test or report—and determining whether the required evidence actually exists.

Used this way, the GSPR becomes a tool for building Technical Documentation and identifying evidence gaps early.

4. Available Doesn't Mean Adequate

One of the biggest mistakes in Technical Documentation gap assessments is asking only:

“Do we have this document?”

A better question is:

“Is this evidence adequate for the device we're certifying?”

A biocompatibility report may exist—but does it cover the same materials, manufacturing process, patient-contacting components and contact duration?

Software verification may exist—but does it cover the current software version?

Clinical evidence may exist—but does it support the current intended purpose and claims?

That's why Available, Applicable and Adequate are three different things.

5. Make Sure the Puzzle Fits

Before submission, consistency and traceability become critical.

Imagine the IFU says the device can be used for seven days, while the Risk Management File and biological evaluation assume only 24 hours.

Every document exists—but together they don't tell a coherent story.

A reviewer should be able to trace important claims through intended purpose, design requirements, verification, clinical evidence, risk management, labeling and PMS.

Likewise, important risks should connect logically to risk controls, design implementation, verification, residual risk and post-market monitoring.

The 80/20 Approach to Technical Documentation

Instead of focusing first on the number of documents completed, focus on five questions:

Do we understand the product and its claims?
Is our regulatory strategy defensible?
Have requirements been translated into evidence needs?
Is our evidence adequate?
Does everything tell the same story?

Strong foundations make the rest of Technical Documentation much easier to structure.

EMD Technical Documentation Roadmap

To support this process, Easy Medical Device created the EMD Technical Documentation Roadmap.

The tool provides a structure for understanding the product, documenting regulatory strategy, mapping requirements, identifying standards and guidance, connecting risks with evidence, assessing gaps, assigning responsibilities, performing consistency checks, and ultimately mapping the documentation into Annex II and Annex III.

Final Takeaway

Stop thinking about Technical Documentation as a collection of folders that need to be filled.

Think about what the reviewer needs to understand:

Is there sufficient, coherent evidence demonstrating that this device conforms with the applicable requirements?

Your Technical Documentation isn't a filing cabinet.

Easy Medical Device Services

CE Marking • MDR • IVDR • Technical Documentation

Medical Device Market Access Services – Easy Medical Device

Back Office Services (BOSS Program)

SmartEye eQMS

SmartEye – eQMS – Easy Medical Device

EasyIFU

Electronic IFU & Label Creation

EasyIFU – Easy Medical Device

Authorized Representative

EU • UK • Switzerland

Worldwide Market Access

Market Access

Market Access

https://easymedicaldevice.com/services/market-access/embed/#?secret=qJuMYs1tqH#?secret=dFwrzZJcuH

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Medical device regulation continues to evolve across multiple markets. For manufacturers, the challenge isn't simply following every new publication—it's understanding which developments require action, which ones need monitoring, and how they affect existing regulatory strategies.

This latest Medical Device Made Easy regulatory update reviews selected developments from July and August 2026 across Europe, Switzerland, the UK, United States, India, Singapore, and Brazil.

🇪🇺 UDI Assignment Under Distributor Branding

Read MDCG 2026-5 – UDI Assignment

MDCG 2026-5 addresses situations where the same medical device is sold under both the manufacturer's brand and a distributor's brand.

Different UDI-DIs may be appropriate, but when the original manufacturer remains the legal manufacturer, the codes must remain assigned by and linked to that manufacturer. This makes existing private-label arrangements, UDI structures, EUDAMED records, and agreements worth reviewing.

🇪🇺 Notified Body Certification & Fee Transparency

Team-NB MDR Certification Process v2.1

European Commission Notified Body Fee Directory

Team-NB's updated consensus paper maps the MDR certification journey from pre-application and quotation through conformity assessment, certification, and surveillance.

Combined with the European Commission's consolidated directory of Notified Body fee pages, these resources can help manufacturers better understand both the certification process and the costs that need to be considered when planning market access.

🇨🇭 swissdamed Registration Becomes Mandatory

Swissmedic – swissdamed Registration Obligation

From 1 July 2026, manufacturers and authorised representatives must register relevant devices, systems, and procedure packs in the swissdamed UDI Devices module.

The general transition period ends on 31 December 2026, making data preparation, responsibility allocation, and reconciliation important operational priorities for companies active in Switzerland.

🇬🇧 MHRA Guidance on Ambient Voice Technology

Read the MHRA Guidance

The MHRA provides useful clarification on when ambient voice technologies, including clinical scribes, may fall within medical device regulation.

Pure transcription or clinician-reviewed administrative summaries may remain outside medical device qualification, while diagnostic insights, treatment recommendations, or medical-performance claims can create a medical intended purpose.

🇺🇸 FDA FY 2027 Medical Device User Fees

FDA FY 2027 Medical Device User Fees

FDA published its FY 2027 medical device user fee notice, covering submission fees, establishment registration, small-business reductions, and related payment procedures.

The new fee year applies from 1 October 2026 through 30 September 2027, making the actual submission receipt date an important consideration when planning budgets.

🇮🇳 CDSCO Medical Device Software Guidance

Read the CDSCO Medical Device Software Guidance

India's CDSCO guidance covers qualification, classification, QMS, technical documentation, clinical evidence, AI-enabled software, cybersecurity, lifecycle change control, and post-market monitoring.

One important message for global manufacturers is that an EU or US classification rationale shouldn't simply be reused without mapping the device and evidence to the Indian framework.

🇸🇬 Singapore Updates Medical Device Cybersecurity Guidance

Singapore HSA Medical Device Guidance

Singapore HSA published an updated Best Practices Guide on Medical Device Cybersecurity in August 2026.

For connected medical devices and software manufacturers, it provides another useful benchmark for secure development, vulnerability management, updates, and post-market cybersecurity activities.

📅 Stay Updated on MedTech Events

Explore MedTech Conferences & Events on MedTechConf

The episode also highlights upcoming opportunities covering Article 117, MDR/IVDR, biocompatibility, AI, clinical evidence, PMS, vigilance, digital health, and African medical device regulation.

🎙️ Continue Learning with Easy Medical Device

Explore the Easy Medical Device Podcast

The July and August catalogue covers audit readiness, FDA clearance, risk management, QMS effectiveness, Intended Use, Master UDI-DI, Verification & Validation, DHF remediation, and global market access.

Easy Medical Device Services

CE Marking • MDR • IVDR • Technical Documentation

Medical Device Market Access Services – Easy Medical Device

Back Office Services (BOSS Program)

SmartEye eQMS

SmartEye – eQMS – Easy Medical Device

EasyIFU

Electronic IFU & Label Creation

EasyIFU – Easy Medical Device

Authorized Representative

EU • UK • Switzerland

Worldwide Market Access

Market Access

https://easymedicaldevice.com/services/market-access/embed/#?secret=LwbhU8XuNP#?secret=MqJ5tTiYnQ

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Developing a medical device successfully requires several pieces to work together. Manufacturers must demonstrate that the product meets its requirements, maintain reliable design documentation, and understand how regulatory expectations differ—or increasingly align—across global markets.

In this Easy Medical Device podcast collection, we explore three connected topics that represent different stages of this journey: Verification & Validation, Design History File remediation, and IMDRF and regulatory reliance.

Making Verification & Validation Practical

Verification and Validation are fundamental parts of medical device development, but the distinction between them can sometimes create confusion.

Verification focuses on whether the device has been developed according to defined requirements, while validation considers whether the resulting device meets its intended use and user needs.

Understanding how to plan and execute V&V effectively helps manufacturers build stronger evidence around device performance and supports a more structured development process.

When Your Design History File Needs Remediation

What happens when the product has already been developed, but the Design History File doesn't properly demonstrate the development journey?

DHF remediation can become necessary when documentation is incomplete, fragmented, poorly traceable, or does not adequately demonstrate how design controls were applied.

The discussion explores the importance of rebuilding those connections and creating documentation that clearly demonstrates the relationship between requirements, design activities, V&V evidence, risk management, and design decisions.

The objective isn't simply to create more documentation. It's to create a coherent and traceable design history.

IMDRF, Regulatory Reliance and Global Market Access

Once a device is ready for market, manufacturers face another challenge: navigating multiple regulatory systems around the world.

The International Medical Device Regulators Forum (IMDRF) plays an important role in encouraging greater regulatory convergence internationally.

Regulatory reliance takes this concept further by allowing authorities, where applicable, to leverage assessments or decisions from other trusted regulatory authorities rather than unnecessarily duplicating the entire review process.

For manufacturers seeking international expansion, understanding these developments can become an important part of building an efficient global market access strategy.

Connecting the Entire Journey

These three topics may appear separate, but they represent a logical progression:

Verification & Validation → Design Documentation → Global Regulatory Approvals

First, manufacturers need evidence that the device performs as expected.

Then, they need documentation that clearly demonstrates how the device was developed and controlled.

Finally, they need a regulatory strategy capable of bringing that device into different markets.

For MedTech companies, getting these elements right can create a stronger foundation for compliance, regulatory submissions, and international market access.

A successful regulatory journey doesn't begin with the submission—it begins with how the device is designed, tested, documented, and prepared for the markets it intends to enter.

Who is Monir El Azzouzi? 

Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. 

Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: [email protected]

 If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.

Bringing a medical device to market requires more than achieving regulatory approval. The decisions made early in product development can influence classification, clinical evidence, risk management, labeling, identification, and ultimately the entire market access strategy.

In this Easy Medical Device podcast collection, we focus on two important regulatory topics: defining a proper Intended Use and understanding Master UDI-DI.

Intended Use: The Foundation of Your Regulatory Strategy

Intended Use may look like a simple statement, but it can influence almost every part of a medical device's regulatory pathway.

A poorly defined Intended Use can create downstream problems with device classification, clinical evaluation, risk management, and regulatory submissions.

Even small changes in wording can have significant consequences, particularly for areas such as Software as a Medical Device (SaMD).

The discussion also explores a common misconception: manufacturers cannot simply use a disclaimer or change their labeling to avoid medical device regulation when the actual intended purpose and claims bring the product within the medical device framework.

Understanding Master UDI-DI

Device identification is another increasingly important part of regulatory strategy.

Master UDI-DI introduces an additional layer that MedTech manufacturers need to understand when managing device identification and regulatory information.

Understanding how it fits into the broader UDI framework can help manufacturers prepare their documentation and data strategy while avoiding mistakes that could create additional regulatory or operational work later.

Building a Stronger Market Access Strategy

Although Intended Use and Master UDI-DI address different regulatory challenges, they share an important principle: regulatory strategy should be considered early rather than treated as an administrative task at the end of development.

Clearly defining your device, understanding its regulatory implications, and preparing the right identification strategy can help create a more predictable path toward market access.

For Regulatory Affairs professionals and medical device manufacturers, these conversations provide practical insights into two topics that can significantly influence the regulatory journey from product development to market.

Who is Monir El Azzouzi? 

Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. 

Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  If you need help implementing QMSR or preparing your teams for FDA inspections, contact: [email protected]

 If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.

Social Media to follow

Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi

Twitter: https://twitter.com/elazzouzim

Pinterest: https://www.pinterest.com/easymedicaldevice

Instagram: https://www.instagram.com/easymedicaldevice

This podcast is hosted by Podcastics, the easiest platform to create and publish your podcast.